Primary study · included by 1 review
Effect of melatonin on quality of life and symptoms in patients with cancer: a systematic review and meta-analysis of randomised controlled trials.
Fan 2022 · Fan Rongrong, Bu Xiaofan, Yang Siyu, et al. · BMJ open · 2022
Included by
| Outcome this study informs | Pooled effect | Evidence | Certainty |
|---|---|---|---|
Fatigue Melatonin (3 to 20 mg/d or 3% oral gel) vs Placebo, no treatment, bright white light therapy or zolpidem | Fatigue (EORTC, FACT-F, MFI-20, VAS): SMD NS (5 RCTs, n = 855) | 5 studies · 855 participants | Very low |
Severe stomatitis (WHO grade) Melatonin (3 to 20 mg/d or 3% oral gel) vs Placebo, no treatment, bright white light therapy or zolpidem | Reducing severe stomatitis (WHO-G) RR NS (3 RCTs, n = 154) | 3 studies · 154 participants | Very low |
Stomatitis incidence (WHO grade) Melatonin (3 to 20 mg/d or 3% oral gel) vs Placebo, no treatment, bright white light therapy or zolpidem | RR 0.47 [0.26, 0.88] | 4 studies · 674 participants | GRADE not reported |
Quality of life Melatonin (3 to 20 mg/d or 3% oral gel) vs Placebo, no treatment, bright white light therapy or zolpidem | QoL (EORTC, FACT) SMD NS (6 RCTs, n = 967) | 6 studies · 967 participants | Very low |
Stomatitis incidence (WHO grade) Melatonin (3 to 20 mg/d or 3% oral gel) vs Placebo, no treatment, bright white light therapy or zolpidem | Stomatitis incidence (WHO-G, NR): RR NS (7 RCTs, n = 832) All cancers | 7 studies · 832 participants | Very low |
Sleep quality Melatonin (3 to 20 mg/d or 3% oral gel) vs Placebo, no treatment, bright white light therapy or zolpidem | Sleep quality (AIS, EORTC, ISI, KSS, MOS, PSQI): SMD NS (9 RCTs, n = 112) | 9 studies · 1128 participants | Very low |
1 including review in total.